MRVI1-AS1 inhibits miR-513a-5p miR-27b-3p to upregulate activating transcription factor 3 (ATF3), then increasing nasopharyngeal cancer’s sensitivity to paclitaxel by modulating the Hippo-TAZ signaling pathway [25]. This evidence concerns the gene ATF3 and nasopharyngeal carcinoma.